Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (501-510 of 520) with videos related to

Pageof 52
Sort By:
European Heart Journal|August 15, 2021
Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fractionAlice M Jackson, Pardeep S Jhund, Inder S Anand, et al.
European Journal of Heart Failure|November 7, 2023
Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trialMorten Schou, Brian Claggett, Zi Michael Miao, et al.
Circulation|November 2, 2022
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI TrialRoxana Mehran, Philippe Gabriel Steg, Marc A Pfeffer, et al.
European Journal of Heart Failure|April 13, 2021
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristicsKarola S Jering, Brian Claggett, Marc A Pfeffer, et al.
European Heart Journal|August 9, 2014
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypesMichele Senni, Walter J Paulus, Antonello Gavazzi, et al.
JACC. Heart Failure|July 15, 2019
Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialAlvin Chandra, Muthiah Vaduganathan, Eldrin F Lewis, et al.
European Journal of Heart Failure|April 12, 2023
Geographic differences in patients with acute myocardial infarction in the PARADISE-MI trialJawad H Butt, Brian L Claggett, Zi M Miao, et al.
Circulation|November 19, 2021
Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI TrialMarc A Pfeffer, Brian Claggett, Eldrin F Lewis, et al.
The New England Journal of Medicine|November 10, 2021
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial InfarctionMarc A Pfeffer, Brian Claggett, Eldrin F Lewis, et al.
Circulation|November 19, 2019
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HFJohn J V McMurray, Alice M Jackson, Carolyn S P Lam, et al.
Pageof 52

Showing results (501-510 of 520) with videos related to

Sort By:
Pageof 52
European Heart Journal|August 15, 2021
Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fractionAlice M Jackson, Pardeep S Jhund, Inder S Anand, et al.
European Journal of Heart Failure|November 7, 2023
Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trialMorten Schou, Brian Claggett, Zi Michael Miao, et al.
Circulation|November 2, 2022
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI TrialRoxana Mehran, Philippe Gabriel Steg, Marc A Pfeffer, et al.
European Journal of Heart Failure|April 13, 2021
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristicsKarola S Jering, Brian Claggett, Marc A Pfeffer, et al.
European Heart Journal|August 9, 2014
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypesMichele Senni, Walter J Paulus, Antonello Gavazzi, et al.
JACC. Heart Failure|July 15, 2019
Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialAlvin Chandra, Muthiah Vaduganathan, Eldrin F Lewis, et al.
European Journal of Heart Failure|April 12, 2023
Geographic differences in patients with acute myocardial infarction in the PARADISE-MI trialJawad H Butt, Brian L Claggett, Zi M Miao, et al.
Circulation|November 19, 2021
Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI TrialMarc A Pfeffer, Brian Claggett, Eldrin F Lewis, et al.
The New England Journal of Medicine|November 10, 2021
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial InfarctionMarc A Pfeffer, Brian Claggett, Eldrin F Lewis, et al.
Circulation|November 19, 2019
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HFJohn J V McMurray, Alice M Jackson, Carolyn S P Lam, et al.
Pageof 52